Trial Profile
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Rupitasertib (Primary) ; Elacestrant; Tamoxifen; Trastuzumab
- Indications HER2 negative breast cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors EMD Serono
- 19 Apr 2023 Results (n=20) assessing the exploratory correlative analyses in ER+ HER2-negative metastatic breast cancer patients in addition to nonclinical experiments to evaluate its role in the CDK4/6 and endocrine therapy (ET) resistant setting, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 06 Apr 2023 According to Diaccurate Media Release, DIACC3010, expectedto enter phase 2/3 clinical trial in refractory ER positive and HER negative Metastatic breast cancer and phase 1 trial in glioblastoma multiforme.
- 06 Apr 2023 According to Diaccurate Media Release, the company has been selected to present new nonclinical efficacy and clinical exploratory correlative analysis of DIACC3010 in metastatic ER positive and HER Negative breast cancer at American Association of Cancer Research (AACR) Annual meeting 2023 in Prlando FL.